Upadacitinib + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Vitiligo
Conditions
Vitiligo
Trial Timeline
Dec 19, 2023 → Feb 1, 2028
NCT ID
NCT06118411About Upadacitinib + Placebo
Upadacitinib + Placebo is a phase 3 stage product being developed by AbbVie for Vitiligo. The current trial status is active. This product is registered under clinical trial identifier NCT06118411. Target conditions include Vitiligo.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06118411 | Phase 3 | Active |
| NCT06012240 | Phase 3 | Recruiting |
| NCT05843643 | Phase 3 | Recruiting |
| NCT05889182 | Phase 3 | Recruiting |
| NCT04927975 | Phase 2 | Completed |
| NCT04430855 | Phase 2 | Completed |
| NCT04169373 | Phase 3 | Completed |
| NCT02955212 | Phase 3 | Completed |
| NCT03178487 | Phase 2 | Completed |
| NCT02925117 | Phase 2 | Completed |
Competing Products
20 competing products in Vitiligo